Next Article in Journal / Special Issue
Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer
Previous Article in Journal
Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods
Previous Article in Special Issue
MALDI Imaging Mass Spectrometry (MALDI-IMS)―Application of Spatial Proteomics for Ovarian Cancer Classification and Diagnosis
Int. J. Mol. Sci. 2011, 12(2), 971-982; doi:10.3390/ijms12020971
Article

Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer

, * ,
,
 and
Received: 20 December 2010; in revised form: 18 January 2011 / Accepted: 18 January 2011 / Published: 31 January 2011
(This article belongs to the Special Issue Cancer Molecules in Ovarian Cancer)
View Full-Text   |   Download PDF [223 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Ovarian cancer, one of the most common gynecological malignancies, has an aggressive phenotype. It is necessary to develop novel and more effective treatment strategies against advanced disease. Protein tyrosine kinases (PTKs) play an important role in the signal transduction pathways involved in tumorigenesis, and represent potential targets for anticancer therapies. In this study, we performed cDNA subtraction following polymerase chain reaction (PCR) using degenerate oligonucleotide primers to identify specifically overexpressed PTKs in ovarian cancer. Three PTKs, janus kinase 1, insulin-like growth factor 1 receptor, and discoidin domain receptor 1 (DDR1), were identified and only DDR1 was overexpressed in all ovarian cancer tissues examined for the validation by quantitative real-time PCR. The DDR1 protein was expressed in 63% (42/67) of serous ovarian cancer tissue, whereas it was undetectable in normal ovarian surface epithelium. DDR1 was expressed significantly more frequently in high-grade (79%) and advanced stage (77%) tumors compared to low-grade (50%) and early stage (43%) tumors. The expression of the DDR1 protein significantly correlated with poor disease-free survival. Although its functional role and clinical utility remain to be examined in future studies, our results suggest that the expression of DDR1 may serve as both a potential biomarker and a molecular target for advanced ovarian cancer.
Keywords: ovarian cancer; tyrosine kinase; DDR1; disease biomarker; cDNA subtraction; degenerate PCR ovarian cancer; tyrosine kinase; DDR1; disease biomarker; cDNA subtraction; degenerate PCR
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Quan, J.; Yahata, T.; Adachi, S.; Yoshihara, K.; Tanaka, K. Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer. Int. J. Mol. Sci. 2011, 12, 971-982.

AMA Style

Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K. Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer. International Journal of Molecular Sciences. 2011; 12(2):971-982.

Chicago/Turabian Style

Quan, Jinhua; Yahata, Tetsuro; Adachi, Sosuke; Yoshihara, Kosuke; Tanaka, Kenichi. 2011. "Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer." Int. J. Mol. Sci. 12, no. 2: 971-982.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert